Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
Status:
Terminated
Trial end date:
2021-08-11
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482)
compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as
assessed by the rate of sustained recovery through Day 29.